Jan 23 (Reuters) - Vigil Neuroscience Inc VIGL.O:
VIGIL NEUROSCIENCE REPORTS POSITIVE DATA FROM ITS PHASE 1 CLINICAL TRIAL EVALUATING VG-3927 FOR THE POTENTIAL TREATMENT OF ALZHEIMER’S DISEASE
VIGIL NEUROSCIENCE INC - VG-3927 TO ADVANCE TO PHASE 2 TRIAL IN Q3 2025
VIGIL NEUROSCIENCE INC - VG-3927 ACHIEVED UP TO 50% REDUCTION OF STREM2 IN CSF
VIGIL NEUROSCIENCE INC - VG-3927 SHOWED FAVORABLE SAFETY AND TOLERABILITY PROFILE
Source text: ID:nGNXqgh0d
Further company coverage: VIGL.O
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。